Health Care/Hospital

ESOC 2025: Combined oral contraceptives triple risk of cryptogenic stroke in young women, new study shows

HELSINKI, May 21, 2025 /PRNewswire/ -- New research presented today at the European Stroke Organisation Conference (ESOC) 2025 revealed that the use of combined oral contraceptives (OCs) is associated with a threefold increase in the risk of cryptogenic ischaemic stroke (CIS) in young women.(1) T...

2025-05-21 06:01 2773

PeproMene Bio, Inc. and the Institute for Follicular Lymphoma Innovation (IFLI) Announce The First Follicular Lymphoma (FL) Patient Treated with BAFF-R Targeting CAR-T Cells (PMB-CT01) Achieves a Complete Response

* The first heavily pretreated r/r FL patient dosed at City of Hope with PMB-CT01 achieved a CR at one-month post treatment. * A Total of 7/7 r/r B-NHL patients including MCL, DLBCL and FL treated with PMB-CT01 have achieved a sustained CR (1 to 29+ months) with strictly grade 1 CRS and ICAN...

2025-05-20 22:22 2253

Race Walking Emerges as the Next Big Cardio Trend: Fast Walking for Optimal Fitness

MIAMI, May 20, 2025 /PRNewswire/ -- Regular walking is universally celebrated as a great way to keep moving, but often it doesn't elevate the heart rate sufficiently for serious cardiovascular benefits. Enter Race Walking—an Olympic Track & Field event since 1904—that combines intense cardio bene...

2025-05-20 22:15 3405

Global Bakery Expo Spotlight: Angel Yeast Launches Feravor™ – A Revolutionary Natural Flavor Solution for Clean-Label Baking

SHANGHAI and DUSSELDORF, Germany, May 20, 2025 /PRNewswire/ -- At Europe's IBA 2025 and Asia's China Bakery Exhibition,Angel Yeast (SH600298) captured global attention with its groundbreaking Feravor™ series. This innovative flavored yeast solution, available in Floral...

2025-05-20 21:54 2967

Antengene Enters into a Global Clinical Collaboration with MSD to Evaluate ATG-022 (CLDN18.2 ADC) In Combination with KEYTRUDA® (pembrolizumab)

- ATG-022 is Antengene's CLDN18.2 antibody-drug conjugate; KEYTRUDA® (pembrolizumab) is MSD's anti-PD-1 therapy. SHANGHAI and HONG KONG, May 20, 2025 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical compa...

2025-05-20 20:00 2727

Rockwell Automation Launches EtherNet/IP In-cabinet Solution to Help Manufacturers Build Smarter, More Efficient Panels

New offering can cut wiring time by up to 80%, speeding production and innovation MILWAUKEE, Wis., May 20, 2025 /PRNewswire/ -- Rockwell Automation, Inc. (NYSE: ROK), the world's largest company dedicated to industrial automation and digital transformation,...

2025-05-20 19:00 2851

Ascletis Announces First Participants Dosed in a U.S. Clinical Study Combining Adipose-Targeted, Once-Monthly Injectable Small Molecule THRβ Agonist, ASC47, and Semaglutide for the Treatment of Obesity

- The combination study is designed to evaluate the safety and preliminary efficacy of a single-dose of ultra-long-acting subcutaneously administered ASC47 in combination with four doses of semaglutide (0.5 mg, once-weekly) in participants with obesity. - Asan adipose-targeted, muscle-preserving...

2025-05-20 18:00 3005

Pulnovo Medical Welcomes EQT as a New Investor Following CE-MDR Approval, with Continued Support from Qiming Venture Partners

HONG KONG, May 20, 2025 /PRNewswire/ -- Pulnovo Medical, a globally recognized pioneer in medical devices for pulmonary hypertension (PH) and heart failure (HF), has received new investment from EQT Group, a top-tier global private equity firm, as a new investor, alongside continued support from ...

2025-05-20 16:53 3510

MediThinQ Enters China Through Strategic Partnership with Sinopharm, Making Wearable Surgical Displays a Reality in Operating Theatres

SINGAPORE, May 20, 2025 /PRNewswire/ -- MediThinQ , the South Korean company specialising in wearable extended reality (XR) surgical displays, announced a strategic partnership with Sinopharm, a state-owned Chinese healthcare giant and the largest pharmaceutical and med...

2025-05-20 12:50 3395

SPOT-MAS Lung: AI-Powered Blood Test Brings New Hope to High-Risk Non-Smokers in Asia

SINGAPORE, May 20, 2025 /PRNewswire/ -- In a bold step toward equitable cancer care,Gene Solutions introduces SPOT-MAS Lung , a next-generation blood-based test powered by artificial intelligence (AI) and multi-omics ...

2025-05-20 10:55 4253

PHASE Scientific Raises US$34 Million Series A Round to Advance Urine-Based Diagnostic Technology for Early Disease Detection

* Largest Series A financing round in Asia's diagnostic technology sector since 2019 underscores strong investor confidence in PHASE Scientific's breakthrough diagnostic technology and growth vision. * Investment to accelerate R&D and commercialization of cutting-edge early disease detection ...

2025-05-20 09:03 3293

Telix at ANZSNM Annual Scientific Meeting 2025

MELBOURNE, Australia, May 20, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix", "the Company") today announces a strong presence at the 55th Annual Scientific Meeting of the Australian and New Zealand Society of Nuclear Medicine (ANZSNM ASM 2025), to be held in M...

2025-05-20 06:00 3106

The Hong Kong Breast Cancer Foundation's 20th Anniversary Gala Dinner Successfully Held

Fundraising to Support Breast Cancer  Patients and Promote Breast Health Education HONG KONG, May 19, 2025 /PRNewswire/ -- Around 600 guests attended the 20th Anniversary Gala Dinner hosted by The Hong Kong Breast Cancer Foundation (HKBCF), raising funds to support breast cancer patients and pr...

2025-05-19 23:47 2424

ANYTIME FITNESS SINGAPORE REACHES MILESTONE OF 125 CLUBS JUST THREE MONTHS INTO 2025

SINGAPORE, May 19, 2025 /PRNewswire/ -- Anytime Fitness Singapore, the nation's leading fitness chain, proudly announces the opening of its 125th club, reaching this milestone just three months into the year. This rapid expansion reinforces the brand's commitment to providing 24-hour access to hi...

2025-05-19 21:30 6056

Shanton to Present Topline Data from Phase 2b Study with SAP-001 in Refractory Gout Patients at EULAR 2025 Congress

SAP-001 is Shanton's lead investigational compound with First- and Best-in-Class potential in uncontrolled gout SINGAPORE and PRINCETON, N.J., May 19, 2025 /PRNewswire/ -- Shanton Pharma, a clinical-stage biotech company developing a novel treatment for gout, today announced that it will be pre...

2025-05-19 21:00 2868

Cell Impact delivers flow plates and test tools to a major player in Asia

KARLSKOGA, Sweden, May 19, 2025 /PRNewswire/ -- Cell Impact AB (publ) has signed an agreement to deliver test tools to a leading industrial player in Asia. The deal confirms Cell Impact's attractive offering and its unique forming technology. The agreement is a follow-up order from a customer wi...

2025-05-19 17:20 2870

Hi & Fi Asia-China 2025: Charting New Frontiers in Health and Food Innovation

SHANGHAI, May 19, 2025 /PRNewswire/ -- Asia's most anticipated trade platform for health ingredients and food innovation, Hi & Fi Asia-China, returns with its landmark 2025 edition from June 24–26 at the National Exhibition and Convention Center (NECC) Shanghai, China. Uniting global leaders in ...

2025-05-19 10:00 4284

VITAMIN ANGELS AND THE MINISTRY OF HEALTH OF INDONESIA HOST MMS MEETING WITH LEADING NATIONAL AND GLOBAL EXPERTS TO REVIEW PROGRESS ON INDONESIA'S "NATIONAL MMS ANTENATAL PROGRAM"

As one of the first countries to implement an end-to-end initiative to integrate MMS and nutrition training into its national health care system, Indonesia aims to reach 4.8 million pregnant women with MMS by 2026 BOGOR, Indonesia, May 19, 2025 /PRNewswire/ -- Vitamin Angels and the Ministry of...

2025-05-19 10:00 2179

CooperVision to Host 5th Asia-Pacific Myopia Management Symposium (APMMS) Alongside Events in the Region

APMMS 2025 is held in partnership with The Hong Kong Association Private Practice Optometrists and The Hong Kong Society of Professional Optometrists and supported by The World Council of Optometry and The World Society of Paediatric Ophthalmology and Strabismus. This year's symposium and surroun...

2025-05-19 09:00 2359

AIM Vaccine's Next-Gen mRNA Shingles Vaccine Secures Clinical Approvals in Both PRC and U.S. ,mRNA Platform Advantages Shine Through

HONG KONG, May 19, 2025 /PRNewswire/ -- While global giants like Moderna and BioNTech apply mRNA technology to broader disease markets, PRC's mRNA frontrunner is keeping pace. AIM Vaccine (06660.HK), a leading domestic vaccine company, announced today that its self-developed mRNA shingles vaccine...

2025-05-19 08:30 6733
1 ... 108109110111112113114 ... 540